IMUNON To Discuss OVATION 1 Clinical Study At Its Sept. 23 R&D Day
IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting IMNN-001, the
IMUNON is sharing results from an important study about a new medicine it's testing. When companies talk about their research, it helps investors understand if the medicine might work, so watch what doctors and scientists say about it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.